Personalized and targeted therapies

被引：0
作者：
Wisniewska, Magdalena [3 ,4 ]
Wisniewski, Michal [5 ]
Lewandowska, Marzena A. [1 ,2 ]
机构：
[1] Nicolaus Copernicus Univ, Coll Med Bydgoszcz, Dept Thorac Surg & Tumors, Torun, Poland
[2] Innovat Med Forum Oncol Ctr, Dept Mol Oncol & Genet, Bydgoszcz, Poland
[3] Nicolaus Copernicus Univ, Coll Med Bydgoszcz, Dept Oncol & Brachytherapy, Torun, Poland
[4] Oncol Ctr, Dept Clin Oncol, Bydgoszcz, Poland
[5] Oncol Ctr, Outpatient Chemotherapy Dept, Bydgoszcz, Poland
来源：
PHYSICAL SCIENCES REVIEWS | 2021年
关键词：
biomarker; predictive biomarkers; tailored treatment; targeted therapies; CELL LUNG-CANCER; METASTATIC COLORECTAL-CANCER; ANAPLASTIC LYMPHOMA KINASE; GROWTH-FACTOR RECEPTOR; WILD-TYPE KRAS; BREAST-CANCER; OPEN-LABEL; RAS MUTATIONS; DOUBLE-BLIND; MONOCLONAL-ANTIBODY;
D O I：
10.1515/psr-2019-0057
中图分类号：
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
Biomarker is defined as indicator of normal or pathogenic biological process or response to an intervention or exposure. There are several categories of biomarkers but predictive biomarkers play the most important role in the treatment of neoplasms. In some cancers there may be more than one potential biomarker, and their identification determines the treatment of the patient. Identification of predictive biomarkers allows the development of novel targeted therapies resulting in tailored treatment. In this chapter we discuss most important predictive biomarkers used in contemporary oncology for which there is approved therapies.
引用
收藏
页码：2103 / 2126
页数：24
相关论文
共 120 条
  • [11] B7 family checkpoint regulators in immune regulation and disease
    Ceeraz, Sabrina
    Nowak, Elizabeth C.
    Noelle, Randolph J.
    [J]. TRENDS IN IMMUNOLOGY, 2013, 34 (11) : 556 - 563
  • [12] Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab
    Cho, HS
    Mason, K
    Ramyar, KX
    Stanley, AM
    Gabelli, SB
    Denney, DW
    Leahy, DJ
    [J]. NATURE, 2003, 421 (6924) : 756 - 760
  • [13] Use of Fluorescence In Situ Hybridization (FISH) in Diagnosis and Tailored Therapies in Solid Tumors
    Chrzanowska, Natalia Magdalena
    Kowalewski, Janusz
    Lewandowska, Marzena Anna
    [J]. MOLECULES, 2020, 25 (08):
  • [14] Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
    Coleman, Robert L.
    Oza, Amit M.
    Lorusso, Domenico
    Aghajanian, Carol
    Oaknin, Ana
    Dean, Andrew
    Colombo, Nicoletta
    Weberpals, Johanne, I
    Clamp, Andrew
    Scambia, Giovanni
    Leary, Alexandra
    Holloway, Robert W.
    Amenedo Gancedo, Margarita
    Fong, Peter C.
    Goh, Jeffrey C.
    O'Malley, David M.
    Armstrong, Deborah K.
    Garcia-Donas, Jesus
    Swisher, Elizabeth M.
    Floquet, Anne
    Konecny, Gottfried E.
    McNeish, lain A.
    Scott, Clare L.
    Cameron, Terri
    Maloney, Lara
    Isaacson, Jeff
    Goble, Sandra
    Grace, Caroline
    Harding, Thomas C.
    Raponi, Mitch
    Sun, James
    Lin, Kevin K.
    Giordano, Heidi
    Ledermann, Jonathan A.
    [J]. LANCET, 2017, 390 (10106) : 1949 - 1961
  • [15] Somatic activation of KIT in distinct subtypes of melanoma
    Curtin, John A.
    Busam, Klaus
    Pinkel, Daniel
    Bastian, Boris C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (26) : 4340 - 4346
  • [16] Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial
    Davies, Christina
    Pan, Hongchao
    Godwin, Jon
    Gray, Richard
    Arriagada, Rodrigo
    Raina, Vinod
    Abraham, Mirta
    Medeiros Alencar, Victor Hugo
    Badran, Atef
    Bonfill, Xavier
    Bradbury, Joan
    Clarke, Michael
    Collins, Rory
    Davis, Susan R.
    Delmestri, Antonella
    Forbes, John F.
    Haddad, Peiman
    Hou, Ming-Feng
    Inbar, Moshe
    Khaled, Hussein
    Kielanowska, Joanna
    Kwan, Wing-Hong
    Mathew, Beela S.
    Mittra, Indraneel
    Mueller, Bettina
    Nicolucci, Antonio
    Peralta, Octavio
    Pernas, Fany
    Petruzelka, Lubos
    Pienkowski, Tadeusz
    Radhika, Ramachandran
    Rajan, Balakrishnan
    Rubach, Maryna T.
    Tort, Sera
    Urrutia, Gerard
    Valentini, Miriam
    Wang, Yaochen
    Peto, Richard
    [J]. LANCET, 2013, 381 (9869) : 805 - 816
  • [17] Mutations of the BRAF gene in human cancer
    Davies, H
    Bignell, GR
    Cox, C
    Stephens, P
    Edkins, S
    Clegg, S
    Teague, J
    Woffendin, H
    Garnett, MJ
    Bottomley, W
    Davis, N
    Dicks, N
    Ewing, R
    Floyd, Y
    Gray, K
    Hall, S
    Hawes, R
    Hughes, J
    Kosmidou, V
    Menzies, A
    Mould, C
    Parker, A
    Stevens, C
    Watt, S
    Hooper, S
    Wilson, R
    Jayatilake, H
    Gusterson, BA
    Cooper, C
    Shipley, J
    Hargrave, D
    Pritchard-Jones, K
    Maitland, N
    Chenevix-Trench, G
    Riggins, GJ
    Bigner, DD
    Palmieri, G
    Cossu, A
    Flanagan, A
    Nicholson, A
    Ho, JWC
    Leung, SY
    Yuen, ST
    Weber, BL
    Siegler, HF
    Darrow, TL
    Paterson, H
    Marais, R
    Marshall, CJ
    Wooster, R
    [J]. NATURE, 2002, 417 (6892) : 949 - 954
  • [18] Molecular Pathways: ROS1 Fusion Proteins in Cancer
    Davies, Kurtis D.
    Doebele, Robert C.
    [J]. CLINICAL CANCER RESEARCH, 2013, 19 (15) : 4040 - 4045
  • [19] Hormone therapy in advanced and recurrent endometrial cancer: a systematic review
    Decruze, S. B.
    Green, J. A.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2007, 17 (05) : 964 - 978
  • [20] MAP kinase signalling pathways in cancer
    Dhillon, A. S.
    Hagan, S.
    Rath, O.
    Kolch, W.
    [J]. ONCOGENE, 2007, 26 (22) : 3279 - 3290
12345678910